Abstract. Microbiology and Infectious Disease / Epidemiology of ESBLs in the Kinki Region of Japan
|
|
- Elmer Gray
- 6 years ago
- Views:
Transcription
1 Microbiology and Infectious Disease / Epidemiology of ESBLs in the Kinki Region of Japan Epidemiology of Escherichia coli, Klebsiella Species, and Proteus mirabilis Strains Producing Extended-Spectrum β-lactamases From Clinical Samples in the Kinki Region of Japan Tatsuya Nakamura, 1,2 Masaru Komatsu, PhD, 3 Katsutoshi Yamasaki, PhD, 4 Saori Fukuda, 5 Yugo Miyamoto, 6 Takeshi Higuchi, 7 Tamotsu Ono, 8 Hisaaki Nishio, 9 Noriyuki Sueyoshi, 1 Kenji Kida, 11 Kaori Satoh, 12 Hirofumi Toda, 12 Masahiro Toyokawa, PhD, 13 Isao Nishi, 13 Masako Sakamoto, 14 Masahiro Akagi, 15 Isako Nakai, 16 Tomomi Kofuku, 17 Tamaki Orita, 18 Yasunao Wada, 19 Takuya Zikimoto, 2 Chihiro Koike, 1 Shohiro Kinoshita, 2 Itaru Hirai, 2 Hakuo Takahashi, MD, 1 Nariaki Matsuura, MD, 2 and Yoshimasa Yamamoto, MD 2 Key Words: Extended-spectrum β-lactamases; Polymerase chain reaction; Surveillance; Replicon type Abstract In the present study, nonduplicate, clinical isolates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, Klebsiella spp, and Proteus mirabilis were collected during a 1-year period from 2 to 29 at several hospitals in the Kinki region, Japan. The detection rate of E coli markedly increased from.24% to 7.25%. The detection rate of Klebsiella pneumoniae increased from % to 2.44% and that of P mirabilis from 6.97% to 12.85%. The most frequently detected genotypes were the CTX-M9 group for E coli, the CTX-M2 group for K pneumoniae, and the CTX-M2 group for P mirabilis. E coli clone O25:H4-ST131 producing CTX-M-15, which is spreading worldwide, was first detected in 27. The most common replicon type of E coli was the IncF type, particularly FIB, detected in 466 strains (69.7%). Of the K pneumoniae strains, 47 (55.3%) were of the IncN type; 77 P mirabilis strains (96.3%) were of the IncT type. In the future, the surveillance of various resistant bacteria, mainly ESBL-producing Enterobacteriaceae, should be expanded to prevent their spread. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae have been increasingly reported worldwide since their first description in Moreover, they have emerged worldwide as a significant cause of community and health care associated infections. 2 ESBLs are the major cause of resistance to oxyimino-cephalosporins in Enterobacteriaceae. ESBLs are mostly plasmid-mediated bacterial enzymes that can hydrolyze a wide variety of penicillins and cephalosporins. Most ESBLs have evolved by genetic mutation from native β-lactamases, particularly TEM-1, TEM-2, and SHV-1. These parent enzymes are commonly found in gram-negative bacteria, particularly in Enterobacteriaceae. 3 Until the 2s, most of the ESBLs were structurally related to the narrowspectrum TEM- and SHV-type β-lactamases, with one to several amino acid substitutions surrounding their active site. During the 199s, they were described mainly as members of the TEM- and SHV-β-lactamase families in Escherichia coli and Klebsiella pneumoniae causing nosocomial outbreaks. 3 Furthermore, in the late 199s, a novel type of ESBL, the CTX-M enzymes, emerged worldwide, mostly from E coli. 3,4 ESBL-producing E coli of the Toho-1-type were reported first in Japan in Nowadays, they are mostly found in E coli that cause community-acquired infections and, with increasing frequency, contain CTX-M enzymes. Moreover, E coli producing a CTX-M-type ESBL is an emerging cause of communityacquired urinary tract infection in young women in the United States, 6 Europe, 7 Hong Kong, 8 India, 9 and elsewhere. Increased community-acquired infection by ESBL-producing bacteria is complicating the selection of therapeutic drugs. More than 5 CTX-M enzymes reported thus far can be grouped into 5 main subgroups according to the similarity of their amino acid sequence (CTX-M-1, CTX-M-2, CTX-M-8, 62 Am J Clin Pathol 212;137: Downloaded 62 from
2 Microbiology and Infectious Disease / Original Article CTX-M-9, and CTX-M-25). 4 In particular, E coli clone O25:H4-ST131 producing CTX-M-15, which is resistant to many antibacterial agents, is spreading worldwide and causing serious problems. 2,1-16 In the present study, nonduplicate clinical isolates of ESBL-positive E coli, Klebsiella spp, and Proteus mirabilis were collected during a 1-year period from 1999 to 29 at several hospitals in the Kinki region, Japan. Our study examined the prevalence and type of β-lactamase genes and plasmid replicon type among the isolates. Moreover, susceptibilities to oral antimicrobial agents were determined. Materials and Methods Bacterial Isolates This laboratory surveillance was conducted with the cooperation of 18 institutions (17 clinical laboratories of various hospitals and 1 commercial laboratory) in the Kinki region, which is located in midwestern Japan. Specimens were collected from 2 to 29. A total of 4,522 isolates of gram-negative bacilli including E coli (25,32 isolates), K pneumoniae (11,582 isolates), Klebsiella oxytoca (2,933 isolates), and P mirabilis (1,187 isolates) were isolated from various clinical specimens, and antimicrobial sensitivity and genotype were tested. A single isolate was selected from each patient and identified by the clinical procedures routinely used in each laboratory. Screening for ESBL The cefpodoxime minimum inhibitory concentration (MIC) criterion of more than 2 μg/ml was used to initially screen isolates. Strains that met the cefpodoxime MIC criterion were investigated by the double-disk synergy (DDS) test with amoxicillin clavulanic acid (2 μg per disk/1 μg per disk), cefotaxime (3 μg per disk), ceftazidime (3 μg per disk), and cefepime (3 μg per disk), according to methods published previously. 17 DDS-positive strains were subjected to polymerase chain reaction (PCR) analyses for the detection of ESBL genes. PCR Amplification for the Detection of ESBL Genes All DDS-positive strains were screened for the resistance genes SHV, TEM, and CTX-M by using a single PCR assay. 18,19 Genetic detection and genotyping of TEM, SHV, and CTX-M were performed by using PCR with bacterial DNA, which was extracted from the isolates by boiling the bacterial suspensions. A solution with an extracted DNA concentration of.1 ng/ml was used as the template for PCR analysis. In the case of genotyping of CTX-M genes, 4 primer sets that amplify group-specific CTX-M genes were used, as described previously: the CTX-M1 group includes CTX-M-1, CTX-M-3, CTX-M-1 to CTX-M-12, CTX-M- 15, CTX-M-22, CTX-M-23, and CTX-M-28 to CTX-M-3; the CTX-M2 group, CTX-M-2, CTX-M-4 to CTX-M-7, CTX-M-2, and Toho-1; the CTX-M8 group, CTX-M-8; and the CTX-M9 group, CTX-M-9, CTX-M-13, CTX-M- 14, CTX-M-16 to CTX-M-19, CTX-M-21, CTX-M-27, and Toho-2. The PCR products were analyzed by using 2% agarose gel electrophoresis and visualized by staining with ethidium bromide. Detection of CTX-M-15 O25:H4-ST131 The serotyping of the CTX-M1 group was carried out by using E coli O and H antisera purchased from Denka Seiken (Tokyo, Japan), according to the manufacturer s instructions. The complete nucleotide sequences of CTX- M1 group O25:H4 E coli genes were determined on both strands by direct sequencing of the PCR products. Multilocus sequence typing (MLST) was performed on 17 strains of CTX-M-15 O25:H4 E coli by following the recommended procedure at the E coli MLST Web site ( dbs/ecoli). Plasmid Replicon Type Determination PCR-based replicon typing was performed on 837 strains as described by Carattoli et al. 2 Eighteen primer pairs targeting the FIA, FIB, FIC, HI1, HI2, I1-Ic, L/M, N, P, W, T, A/C, K, B/O, X, Y, F, and FII replicons were used in separate PCR reactions. Susceptibility to Oral Antimicrobial Agents The susceptibilities to oral antimicrobial agents, amoxicillin-clavulanic acid (AMC), minocycline, levofloxacin, fosfomycin, colistin, and trimethoprim-sulfamethoxazole (SXT), were determined by the broth diffusion method on Mueller-Hinton agar (Eiken Chemical, Tokyo, Japan), according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). 21 The quality control strains used in this study were E coli ATCC and E coli ATCC Throughout this study, the results were interpreted using CLSI criteria for broth dilution. 22 Results ESBL Detection Between 2 and 29, a total of 4,522 strains, including 25,32 E coli, 11,582 K pneumoniae, 2,933 K oxytoca, and 1,187 P mirabilis strains, were analyzed. ESBL isolation rates are shown in Figure 1 and Table 1. The detection of ESBL-producing E coli markedly increased Downloaded from Am J Clin Pathol 212;137:
3 Nakamura et al / Epidemiology of ESBLs in the Kinki Region of Japan No. of Isolates 3 1 P mirabilis 9 25 K oxytoca K pneumoniae 8 E coli 7 2 Detection rate (all strains) Figure 1 Distribution of detection among extended-spectrum β-lactamase (ESBL)-positive Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and Proteus mirabilis in hospitals and associated health care facilities, from 2 strains (.24%) in 2 to 224 strains (7.25%) in 29. The detection of ESBL-producing K pneumoniae increased from (.%) to 3 strains (2.44%) and that of ESBL-producing K oxytoca increased from (.%) to 3 strains (1.18%). The detection of ESBL-producing P mirabilis increased from 14 (6.97%) to 23 strains (12.85%) in a survey conducted since 24. In the whole of the Kinki region, the detection rate increased from.42% (between 2 and 24) to 3.4% (between 25 and 29). Molecular Detection of ESBL The changes in the genotypes detected during the survey period are shown in Figure 2 for E coli and in Figure 3 for K pneumoniae. The most frequently detected genotypes in the 1 years were the CTX-M9 group for E coli (374 Detection Rate (%) No. of Isolates TEM group SHV group CTX-M9 group CTX-M8 group CTX-M2 group CTX-M1 group Figure 2 Distribution of different extended-spectrum β-lactamase (ESBL) genes among ESBL-positive Escherichia coli isolates detected in hospitals and associated health care facilities, The CTX-M1 group includes CTX-M-1, CTX-M-3, CTX-M-1 to CTX-M-12, CTX-M-15, CTX-M-22, CTX-M-23, and CTX-M-28 to CTX-M-3; the CTX-M2 group, CTX-M-2, CTX-M-4 to CTX-M-7, CTX-M-2, and Toho-1; the CTX-M8, group, CTX-M8; and the CTX-M9 group, CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-16 to CTX-M-19, CTX-M-21, CTX-M-27, and Toho-2. strains [55.9%]), the CTX-M2 group for K pneumoniae (38 strains [44.7%]), and the CTX-M2 group for P mirabilis (79 strains [98.8%]). The detection number of E coli of the CTX-M9 group increased from 25 strains to 144 strains from 25. In addition, the detection number of E coli of the CTX-M1 group increased from 11 strains to 57 strains from 25. The detection number of K pneumoniae of the CTX-M9 group increased from 26. The detection rates Table 1 Number of Isolates of ESBL in Each Term * Organism Total Escherichia coli Collected strains 82 1,297 3,13 3,95 2,813 2,429 3,62 2,86 2,897 3,88 25,32 ESBL 2 (.24) 7 (.54) 15 (.5) 12 (.39) 15 (.53) 62 (2.55) 89 (2.91) 11 (3.6) 142 (4.9) 224 (7.25) 669 (2.64) Klebsiella pneumoniae Collected strains ,487 1,468 1,144 1, ,25 1,237 1,229 11,82 ESBL (.) 1 (.11) 7 (.47) 4 (.27) (.) 1 (.87) 5 (.7) 8 (.66) 2 (1.62) 3 (2.44) 85 (.77) Klebsiella oxytoca Collected strains ,933 ESBL (.) (.) (.) (.) (.) (.) (.) (.) (.) 3 (1.18) 3 (.1) Proteus mirabilis Collected strains ND ND ND ND ,187 ESBL ND ND ND ND 14 (6.97) 6 (2.8) 3 (2.54) 1 (3.98) 24 (1.71) 23 (12.85) 8 (6.74) Total Collected strains 1,516 2,431 4,9 4,919 4,541 4,18 4,99 4,63 4,655 4,75 4,522 ESBL 2 (.13) 8 (.33) 22 (.45) 16 (.33) 29 (.64) 78 (1.9) 97 (2.37) 119 (2.59) 186 (4.) 28 (5.89) 837 (2.7) ESBL, extended-spectrum β-lactamase; ND, not done. * Data are given as number or number (percentage). 622 Am J Clin Pathol 212;137: Downloaded 622 from
4 Microbiology and Infectious Disease / Original Article Prevalence of Plasmid Replicons The most common replicon type of E coli was the IncF type, particularly FIB, detected in 466 strains (69.7%), followed by FIA in 336 strains (5.2%), I1-1 in 83 strains (12.4%), and N in 65 strains (9.7%) Table 2. Of the K pneumoniae strains, 47 (55.3%) were of the N type. Most of the bacteria carried a single plasmid, but some bacteria carried multiple plasmid types. The average number of plasmids carried by the bacteria was from 1 to 1.5. Of the P mirabilis strains, 77 (96.3%) were of the IncT type. No. of Isolates TEM group SHV group CTX-M9 group CTX-M8 group CTX-M2 group CTX-M1 group Figure 3 Distribution of different extended-spectrum β-lactamase (ESBL) genes among ESBL-positive Klebsiella pneumoniae isolates detected in hospitals and associated health care facilities, The CTX-M1 group includes CTX-M-1, CTX-M-3, CTX-M-1 to CTX-M-12, CTX-M-15, CTX-M-22, CTX-M-23, and CTX-M-28 to CTX-M-3; the CTX-M2 group, CTX-M-2, CTX-M-4 to CTX-M-7, CTX-M-2, and Toho-1; the CTX-M8 group, CTX-M8; and the CTX-M9 group, CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-16 to CTX-M- 19, CTX-M-21, CTX-M-27, and Toho-2. of the SHV/TEM groups were as follows: SHV group, 19 strains (2.8%) and TEM group, 6 strains (.9%) for E coli; SHV group, 14 strains (16.5%) and TEM group, 2 strains (2.4%) for K pneumoniae. The E coli clone O25:H4-ST131 producing CTX-M-15, which is spreading worldwide, was first detected in 27. In the 3 subsequent years, 17 strains (3 in 27, 1 in 28, and 4 in 29) were detected. Susceptibility for Oral Drug Oral drug susceptibility rates Table 3 for E coli were 96.% for colistin, 93.7% for fosfomycin, 62.6% for minocycline, 47.2% for AMC, 44.3% for SXT, and 32.2% for levofloxacin. The levofloxacin susceptibility rate was the highest for the CTX-M2 group genotype. The drug susceptibility rates for K pneumoniae were 86.9% for levofloxacin, 86.9% for colistin, 83.3% for fosfomycin, 51.2% for AMC, 46.4% for SXT, and 21.4% for minocycline. The SXT susceptibility rate was the lowest (%) for the TEM/SHV group genotype. Drug susceptibility rates for P mirabilis were 1% for AMC, 64.6% for SXT, 5.6% for fosfomycin, 15.2% for levofloxacin,.% for colistin, and.% for minocycline. The AMC susceptibility rate was 1%. Discussion In this study, long-term surveillance between 2 and 29 demonstrated that ESBL-producing E coli increased about 3 times from.24% to 7.25% in 1 years. According Table 2 Number of Replicons in Parental Strains of ESBL-Producing Strains * Replicon Type All Strain/Genotype Replicon Types Non- Group (No. of Isolates) A/C FII FIA FIB FIC H12 HI1 HI2 I1-1 K L/M N P T Y type Total Mean Escherichia coli CTX-M1 (174) CTX-M2 (95) CTX-M9 (374) SHV (19) TEM (6) Klebsiella pneumoniae CTX-M1 (16) CTX-M2 (38) CTX-M9 (14) Proteus mirabilis CTX-M2 (79) ESBL, extended-spectrum β-lactamase. * The CTX-M1 group included CTX-M-1, CTX-M-3, CTX-M-1 to CTX-M-12, CTX-M-15, CTX-M-22, CTX-M-23, and CTX-M-28 to CTX-M-3; the CTX-M2 group, included CTX-M-2, CTX-M-4 to CTX-M-7, CTX-M-2, and Toho-1; and the CTX-M9 group, CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-16 to CTX-M-19, CTX-M-21, CTX-M-27, and Toho-2. Average plasmid-carrying rate. Downloaded from Am J Clin Pathol 212;137:
5 Nakamura et al / Epidemiology of ESBLs in the Kinki Region of Japan Table 3 Susceptibility of Oral Antibiotics in Each ESBL * Escherichia coli Klebsiella pneumoniae Proteus mirabilis Antibiotic CTX-M1 CTX-M2 CTX-M9 SHV/TEM Total CTX-M1 CTX-M2 CTX-M9 SHV/TEM Total CTX-M2 Levofloxacin Minocycline SXT Fosfomycin AMC Colistin AMC, amoxicillin clavulanic acid; ESBL, extended-spectrum β-lactamase; SXT, trimethoprim-sulfamethoxazole. * Susceptibility data are given as percentages according to the criteria of the Clinical and Laboratory Standards Institute (M1-S2) for Enterobacteriaceae. The CTX-M1 group includes CTX-M-1, CTX-M-3, CTX-M-1 to CTX-M-12, CTX-M-15, CTX-M-22, CTX-M-23, and CTX-M-28 to CTX-M-3; the CTX-M2 group, CTX-M-2, CTX-M-4 to CTX-M-7, CTX-M-2, and Toho-1; and the CTX-M9 group, CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-16 to CTX-M-19, CTX-M-21, CTX-M-27, and Toho-2. to Fang et al, 22 ESBL-producing E coli increased by about 1 times between 21 and 26 in Sweden, a result comparable with that from a different survey conducted in the same period. Recently, many reports have been made on intestinal bacteria that acquired genes such as KPC 23 and NDM Until now, ESBL-producing E coli have rarely been detected in Japan. This study may be useful for the prediction of resistant bacteria in the future. Our study revealed the changes in the ESBL genotypes of ESBL-producing E coli, Klebsiella spp, and P mirabilis in the Kinki region of Japan. Shibata et al 25 investigated ESBLproducing intestinal bacteria of the CTX-M group in Japan. They reported that 89 of 168 E coli strains belonged to the CTX-M9 group. In particular, the CTX-M9 group, frequently detected in E coli, is presumably the most common genotype in Japan. Similarly, in this study, 374 of 669 E coli strains were of the CTX-M9 group. In particular, contrary to the decreased CTX-M2 group, the CTX-M9 group has increased since 27. The CTX-M2 group is frequently detected in food products such as meat. 26 It was thought that usage restrictions of the antimicrobial agent to domestic animals had influenced a decrease of CTX-M-2. On the other hand, the CTX-M1 group has slightly increased. In Japan, the trend of the E coli clone O25:H4-ST131 producing CTX-M-15, which causes problems worldwide, is unknown. Hawkey 1 reported trends of increase in Asia. In addition, detection in India and Pakistan were reported. The problem is that this strain is detected in hospital- and community-acquired urinary tract infections and develops multidrug resistance. This study demonstrated that the E coli clone O25:H4-ST131 producing CTX-M-15 was detected in 27 or later, suggesting the continuing existence of this strain in Japan. At present, community-acquired infection with this strain is uncommon. However, attention should be given to future trends. The study of plasmid replicon types provides information about the spread and risks of ESBL-producing bacteria. The genes responsible for CTX-M β-lactamases are encoded by plasmids belonging to the narrow host-range incompatibility types (ie, IncFI, IncFII, IncHI2, and IncI) or the broad host-range incompatibility types (ie, IncN, IncP-1-a, IncL/M, and IncA/C). 27 In this study, the IncF group predominated among the E coli strains, regardless of their genotypes. Many strains acquired multiple plasmids. Similar results have been obtained in other studies. 28 About 1% of the strains were of the I1-1- and N-types, suggesting the existence of various E coli clones. The spread of community-acquired infection indicates the potential spread of these various clones in different forms. On the other hand, the N-type predominated among K pneumoniae strains and the T-type among the P mirabilis strains, suggesting the spread of a single clone or plasmid. Many reports have been published particularly on these 2 strains in hospital-acquired infection In addition, in this study, both species were occasionally detected in the same facility and ward, suggesting an epidemiology different from that of E coli. Bacterial properties vary with species. Thus, measurements should be done carefully, according to the species. Recently, the spread of community-acquired infection by ESBL-producing strains of the CTX-M type is causing problems. Reportedly, more ESBL-producing strains have been detected in females with urinary tract infection. 6-9 The spread of community-acquired infection complicates the selection of antibacterial agents for outpatient care. Few oral antibacterial agents effective against ESBL-producing bacteria are available. According to recent reports, quinolone resistance is regarded as a serious problem. 32 In addition, in this study, quinolone-resistance rates were high among the E coli strains: about 7% of the strains were resistant. In particular, the resistance rate of the CTX-M1 group was the highest (about 85%). Thus, quinolones cannot be used for the treatment of those infectious diseases. The susceptibility of E coli to fosfomycin is being maintained. The reason for it will be that 3 g/d is recommended, as described in the Sanford guidelines. 33 On the other hand, 8% of the K pneumoniae strains are susceptible 624 Am J Clin Pathol 212;137: Downloaded 624 from
6 Microbiology and Infectious Disease / Original Article to quinolones. Thus, quinolones should be effective for K pneumoniae. Antibacterial susceptibility varies with strains and genotypes. Thus, antibacterial agents for areas should be selected on the basis of the results obtained by studies on the epidemiologic backgrounds of those areas. The detection rate of the ESBL-producing E coli in our institutions was low, in comparison with that in Western countries and other areas in Asia. One of the reasons for this may be the difference in the type of antibiotics used in these countries: carbapenems and oxacephems, in particular, have often been used in Japan. Because ESBL-producing bacteria are susceptible to these drugs, they might have suppressed the diffusion of these bacteria. However, recently, reduced use of these drugs is recommended in clinical settings to avoid the overall resistance to these antibiotics. This may lead to an increase of the ESBL-producing bacteria in the near future in Japan. This report described the epidemiologic trends of ESBLproducing E coli, Klebsiella spp, and P mirabilis in Japan. Various causative genes are known for β-lactam resistant intestinal bacteria. Many reports have been published on serious resistant bacteria (eg, KPC, NDM-1, CTX-M-15) worldwide. In the future, the surveillance of various resistant bacteria, mainly ESBL-producing bacteria, should be expanded to prevent their spread. From the Departments of Clinical Laboratory, 1 Kansai Medical University Hirakata Hospital, Osaka, Japan; 4 Wakayama Rosai Hospital, Wakayama, Japan; and 15 Osaka Police Hospital, Osaka; 2 Division of Biomedical Informatics, Course of Health Science, Graduate School of Medicine, Osaka University, Osaka; 3 Bacteriological Testing Section of Central Laboratory, FALCO Biosystems, Kyoto, Japan; 5 Department of Clinical Pathology, Tenri Hospital, Nara, Japan; Clinical Laboratory, 6 National Hospital Organization Minami Wakayama Medical Center, Wakayama, Japan; 8 Kyoto Second Red Cross Hospital, Kyoto; 9 Shiga Medical Center for Adults, Shiga, Japan; 1 Social Insurance Shiga Hospital, Shiga; 11 Japanese Red Cross Otsu Hospital, Shiga; 14 The Research Foundation for Microbial Diseases of Osaka University, Osaka; 16 Sumitomo Hospital, Osaka; 17 Hyogo Prefectural Amagasaki Hospital, Hyogo, Japan; 18 Takarazuka Municipal Hospital, Hyogo; 19 Hyogo Medical University Hospital, Hyogo; and 2 Kobe University Hospital, Hyogo; 7 Laboratory for Clinical Investigation, Kyoto University Hospital, Kyoto; 12 Department of Medical Technology, Kinki University School of Medicine, Osaka; and 13 Laboratory for Clinical Investigation, Osaka University Hospital, Osaka. Supported by the Study Group of Bacterial Resistance in the Kinki Region of Japan. Address reprint requests to Tatsuya Nakamura: Dept of Clinical Laboratory, Kansai Medical University Hirakata Hospital, Shinmachi, Hirakata City, Osaka, , Japan. Acknowledgments: We are grateful to K. Yamane and Y. Arakawa, Department of Bacterial and Blood Products, National Institute of Infectious Diseases, Tokyo, Japan. References 1. Knothe H, Shah P, Krcmery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11: Pitout JD, Hossain A, Hanson ND. Phenotypic and molecular detection of CTX-M-β-lactamases produced by Escherichia coli and Klebsiella spp. J Clin Microbiol. 24;42: Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 21;14: Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 24;48: Matsumoto Y, Ikeda F, Kamimura T, et al. Novel plasmidmediated β-lactamase from Escherichia coli that inactivates oxyimino-cephalosporins. Antimicrob Agents Chemother. 1988;32: Doi Y, Adams J, O Keefe A, et al. Community-acquired extended-spectrum β-lactamase producers, United States. Emerg Infect Dis. 27;13: Woodford N, Ward ME, Kaufmann ME, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 24;54: Ho PL, Poon WW, Loke SL, et al. Community emergence of CTX-M type extended-spectrum β-lactamases among urinary Escherichia coli from women. J Antimicrob Chemother. 27;6: Freeman JT, McBride SJ, Heffernan H, et al. Communityonset genitourinary tract infection due to CTX-M-15 producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clin Infect Dis. 28;47: Hawkey PM. Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clin Microbiol Infect. 28;14: Lewis JS Jr, Herrera M, Wickes B, et al. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a US health care system. Antimicrob Agents Chemother. 27;51: Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 27;59: Mulvey MR, Bryce E, Boyd E, et al. Ambler class A extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp in Canadian hospitals. Antimicrob Agents Chemother. 24;48: Rossolini GM, D Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum β-lactamases. Clin Microbiol Infect. 28;14: Villegas MV, Kattan JN, Quinteros MG, et al. Prevalence of extended-spectrum β-lactamases in South America. Clin Microbiol Infect. 28;14: Zong Z, Partridge SR, Thomas L, et al. Dominance of blactx-m within an Australian extended-spectrum β-lactamase gene pool. Antimicrob Agents Chemother. 28;52: Tzelepi E, Giakkoupi P, Sofianou D, et al. Detection of extended spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol. 2;38: Downloaded from Am J Clin Pathol 212;137:
7 Nakamura et al / Epidemiology of ESBLs in the Kinki Region of Japan 18. Arlet G, Philippon A. Construction by polymerase chain reaction and use of intragenic DNA probes for three main types of transferable β-lactamases (TEM, SHV, CARB). FEMS Microbiol Lett. 1991;66: Pitout JD, Laupland KB. Extended-spectrum β-lactamase producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 28;8: Carattoli A, Bertini A, Villa L, et al. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 25;63: Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 21. Document M1-S Fang H, Ataker F, Hedin G, et al. Molecular epidemiology of extended-spectrum β-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 21 to 26. J Clin Microbiol. 28;46: Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 21;45: Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-β-lactamase gene, bla(ndm-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 29;53: Shibata N, Kurokawa H, Doi Y, et al. R classification of CTX-M-type β-lactamase genes identified in clinically isolated gram-negative bacilli in Japan. Antimicrob Agents Chemother. 26;5: Warren RE, Ensor VM, O Neill P, et al. Imported chicken meat as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 28;61: Marcadé G, Deschamps C, Boyd A, et al. Replicon typing of plasmids in Escherichia coli producing extended-spectrum β-lactamases. J Antimicrob Chemother. 29;63: Elhani D, Bakir L, Aouni M, et al. Molecular epidemiology of extended-spectrum β-lactamase producing Klebsiella pneumoniae strains in a university hospital in Tunis, Tunisia, Clin Microbiol Infect. 21;16: Mena A, Plasencia V, García L, et al. Characterization of a large outbreak by CTX-M-1 producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol. 26;4: Nagano N, Shibata N, Saitou Y, et al. Nosocomial outbreak of infections by Proteus mirabilis that produces extendedspectrum CTX-M-2 type β-lactamase. J Clin Microbiol. 23;41: Gruteke P, Goessens W, van Gils J, et al. Patterns of resistance associated with integrons, the extended-spectrum β-lactamase SHV-5 gene, and a multidrug efflux pump of Klebsiella pneumoniae causing a nosocomial outbreak. J Clin Microbiol. 23;41: Jones GL, Warren RE, Skidmore SJ, et al. Prevalence and distribution of plasmid-mediated quinolone resistance genes in clinical isolates of Escherichia coli lacking extended-spectrum β-lactamases. J Antimicrob Chemother. 28;62: Gilbert DN, Moellering RC, Eliopoulos GM, et al. The Sanford Guide to Antimicrobial Therapy st ed. Hyde Park, VT: Antimicrobial Therapy; Am J Clin Pathol 212;137: Downloaded 626 from
Klebsiella pneumoniae 21 PCR
2011 11 TEM-132 ESBL Klebsiella pneumoniae 1) 2) 1) 1) 3) 2) 1) 2) 3) 19 6 27 22 10 20 2003 4 2004 11 95 ceftazidime (CAZ) Klebsiella pneumoniae 21 PCR b- (ESBL) PCR (PFGE) PCR bla TEM-132 PFGE 19 TEM-132
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationEmergence of non-kpc carbapenemases: NDM and more
Emergence of non-kpc carbapenemases: NDM and more --- David Livermore Health Protection Agency, UK The first acquired carbapenemase to be recognised in gram-negative bacteria was IMP-1, a metallo-type,
More informationMolecular characterisation of CTX-M-type extendedspectrum β-lactamases of Escherichia coli isolated from a Portuguese University Hospital
EJHP Science Volume 17 2011 Issue 3 P. 1-5 2011 Pharma Publishing and Media Europe. All rights reserved 1781-7595 25 www.ejhp.eu Molecular characterisation of CTX-M-type extendedspectrum β-lactamases of
More informationEnterobacteriaceae with acquired carbapenemases, 2016
Enterobacteriaceae with acquired carbapenemases, 2016 Background The acquired or transferable (as opposed to chromosomally encoded) carbapenemases found in Enterobacteriaceae belong to three of the four
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More informationEmergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH
Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationST11 KPC-2 Klebsiella pneumoniae detected in Taiwan
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05576-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationEnterobacteriaceae with acquired carbapenemases, 2015
Enterobacteriaceae with acquired carbapenemases, 2015 Background The acquired or transferable (as opposed to chromosomally encoded) carbapenemases found in Enterobacteriaceae belong to three of the four
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationDownloaded from ismj.bpums.ac.ir at 10: on Friday March 8th 2019
- ( ) - * :... (MDR) (ESBLs: Extended-Spectrum Beta Lactamases). :.. (CLSI:Clinical and Laboratory Standards Institute). ESBL. combined disk method ESBL : / / / / / B / ( /). / / combined disk method.
More informationJournal of Infectious Diseases and
Journal of Infectious Diseases & Therapy ISSN: 2332-0877 Journal of Infectious Diseases and Therapy Santanirand et al., J Infect Dis Ther 2018, 6:5 DOI: 10.4172/2332-0877.1000378 Research Article Open
More informationjmb Research Article Review Semi Kim 1, Ji Youn Sung 2, Hye Hyun Cho 3, Kye Chul Kwon 1, and Sun Hoe Koo 1 *
J. Microbiol. Biotechnol. (2014), 24(6), 765 770 http://dx.doi.org/10.4014/jmb.1306.06036 Review Research Article jmb Characterization of CTX-M-14- and CTX-M-15-Producing Escherichia coli and Klebsiella
More informationEscherichia coli b- Extended spectrum b-lactamase (ESBL) 8 (6.5 ), Cephalosporinase (Amp- Amp-C 2. IncF (FIA,FIB) group ESBL 6 Amp-C 4
2011 193 Escherichia coli b- 22 12 20 23 5 30 b- 2006 1 2009 9 744 Escherichia coli b- 4,211 E. coli 123 (2.9) 124 CAZ AZT MIC 2 mg/ml 12 (9.8) 13 Extended spectrum b-lactamase (ESBL) 8 (6.5), Cephalosporinase
More informationEpidemiology of ESBL in hospitals and in the community
Epidemiology of ESBL in hospitals and in the community Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L C Y M R
More informationRapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann
Rapid identification of emerging resistance in Gram negatives Prof. Patrice Nordmann Emerging Resistance threats, CDC USA-2013 Enterobacteriaceae producing extendedspectrum β-lactamases (ESBL) Multi-resistant
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationRevised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in
AAC Accepts, published online ahead of print on 3 December 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01180-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationDifferentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test
Original article: Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test Manish Bansal 1, Nitya Vyas 2, Babita Sharma 3, R.K.Maheshwari 4 1PG Resident, 2 Professor, 3 Assistant
More informationbreakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1):
REVIEW Breakpoints for intravenously used cephalosporins in Enterobacteriaceae EUCAST and CLSI breakpoints G. Kahlmeter Department of Clinical Microbiology, Central Hospital, Växjö, Sweden ABSTRACT It
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationCarbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan An Infection Control Emergency Speaker: L Kristopher Siu Principal Investigator Division of Infectious Diseases National Institute
More informationLaboratory Surveillance for Prospective Plasmid-Mediated AmpC -Lactamases in the Kinki Region of Japan
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2010, p. 3267 3273 Vol. 48, No. 9 0095-1137/10/$12.00 doi:10.1128/jcm.02111-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Laboratory
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More information#Corresponding author: Pathology Department, Singapore General Hospital, 20 College. Road, Academia, Level 7, Diagnostics Tower, , Singapore
AAC Accepts, published online ahead of print on 21 October 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01754-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Title: Escherichia
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationDetection of NDM-1-producing Klebsiella pneumoniae in Kenya
AAC Accepts, published online ahead of print on 29 November 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.01247-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationPROFESSOR PETER M. HAWKEY
Multi-drug resistant Escherichia coli PROFESSOR PETER M. HAWKEY School of Immunity and Infection College of Medical and Dental Sciences University of Birmingham Birmingham B15 2TT Health Protection Agency
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationJOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1998, p Vol. 36, No. 9. Copyright 1998, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1998, p. 2575 2579 Vol. 36, No. 9 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Can Results Obtained with Commercially
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationReceived 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1965 1969 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00203-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparative
More informationInternational transfer of NDM-1-producing Klebsiella. pneumoniae from Iraq to France
AAC Accepts, published online ahead of print on 18 January 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01761-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationExtended-Spectrum -Lactamases: a Clinical Update
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2005, p. 657 686 Vol. 18, No. 4 0893-8512/05/$08.00 0 doi:10.1128/cmr.18.4.657 686.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Extended-Spectrum
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationStrain-specific transmission in an outbreak of ESBL-producing Enterobacteriaceae in the hemato-oncology care unit: a cohort study
Uemura et al. BMC Infectious Diseases (2017) 17:26 DOI 10.1186/s12879-016-2144-4 RESEARCH ARTICLE Open Access Strain-specific transmission in an outbreak of ESBL-producing Enterobacteriaceae in the hemato-oncology
More informationEnterobacteriaceae in Bamako, Mali. Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière, CHU Reims, UFR Médecine
AAC Accepts, published online ahead of print on 31 August 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.00675-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationEVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS
Indian Journal of Medical Microbiology, (2005) 23 (2):120-124 Brief Communication EVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS S Singhal, T
More informationCephalosporin MIC Distribution of Extended-Spectrum- -Lactamaseand pampc-producing Escherichia coli and Klebsiella Species
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2009, p. 2419 2425 Vol. 47, No. 8 0095-1137/09/$08.00 0 doi:10.1128/jcm.00508-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Cephalosporin
More informationMulti-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis
JCM Accepts, published online ahead of print on 30 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00678-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Multi-clonal origin
More informationEpidemiology of the β-lactamase resistome among Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae in the Chicago region
Epidemiology of the β-lactamase resistome among Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae in the Chicago region Michael Y. Lin MD MPH 1, Karen Lolans BS 1, Rosie D. Lyles,
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationTHE INVASION BY CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE
ANKEM Derg 2012;26(Ek 2):31-35 THE INVASION BY CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE Patrice NORDMANN Service de Bactériologie-Virologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre, South-Paris Medical
More informationClinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes
56 Clinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes Patrick N. A. Harris, BSc, MBBS, MRCP, DTM&H, FRACP, FRCPA 1 1 Infection and
More information(multidrug-resistant Pseudomonas aeruginosa; MDRP)
220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM
More informationDetection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by MALDI- TOF mass spectrometry
JCM Accepts, published online ahead of print on 2 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.01002-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12
More informationSensitive and specific Modified Hodge Test for KPC and metallo-beta-lactamase
JCM Accepts, published online ahead of print on 19 October 2011 J. Clin. Microbiol. doi:10.1128/jcm.05602-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationAbstract. a Jann-Tay Wang 1, Un-In Wu 2, Tsai-Ling Yang Lauderdale 3, Mei-Chen Chen 3, Shu-Ying Li 4, Le-Yin Hsu 5, Shan-Chwen Chang 1,6 *
RESEARCH ARTICLE Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan Jann-Tay Wang 1, Un-In Wu 2, Tsai-Ling Yang Lauderdale 3, Mei-Chen Chen 3, Shu-Ying Li 4, Le-Yin Hsu 5, Shan-Chwen Chang 1,6 * 1
More informationClinical Microbiology Newsletter
Clinical Microbiology Newsletter $88 Vol. 30, No. 10 www.cmnewsletter.com May 15, 2008 Newer β-lactamases: Clinical and Laboratory Implications, Part I * Ellen Smith Moland, B.S.M.T., Soo-Young Kim, M.D.,
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationDisclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program
47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax
More informationDetecting CRE. what does one need to do?
5 th ICAN Conference, Harare 4 th November 2014 Room 2: 10:30-12:00 Detecting CRE (Carbapenem-resistant Enterobacteriaceae) what does one need to do? Dr Nizam Damani Associate Medical Director Infection
More informationKPC around the world Maria Virginia Villegas, MD, MSC
KPC around the world Maria Virginia Villegas, MD, MSC Scientific Director Bacterial Resistance and Nosocomial Infections Research Area International Center for Medical Research and Training, CIDEIM, Cali,
More informationDetection of Carbapenem Resistant Enterobacteriacae from Clinical Isolates
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 5 (2016) pp. 864-869 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.505.089
More informationInsert for Kit 98006/98010/ KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J
Insert for Kit 98006/98010/98015 KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J DATE OF ISSUE: 09.02.2017 LANGUAGE: English FOR IN VITRO DIAGNOSTIC
More informationFirst description of KPC-2-producing Pseudomonas putida in Brazil. Anna C. S. Almeida, Marinalda A. Vilela*, Felipe L.S. Cavalcanti, Willames M.B.S.
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05268-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 First description
More informationResistance to Polymyxins in France
Resistance to Polymyxins in France Paris Prof. Patrice Nordmann NDM producers in Enterobacteriaceae The polymyxins; colistin and polymyxin B Colistin - Synthesis by Bacillus polymyxa spp colistinus -
More informationScreening of Carbapenem Resistant Enterobacteriaceae among Nosocomial Isolates: A Study from South India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 4 (2017) pp. 460-465 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.604.053
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More informationCarbapenems and Enterobacteriaceae
Title Carbapenems and Enterobacteriaceae Presenter s details NHLS Dr Khine Swe Swe/Han FC Path ( Micro), SA MMed( micro), SA DTMH(Wits univ),sa PDIC(Stellen univ)sa MB,BS(Yangon),Myanmar Pathologist,Consultant/Lecturer,
More informationA new diagnostic microarray (Check-KPC ESBL) for detection and. identification of extended-spectrum beta-lactamases in highly resistant
JCM Accepts, published online ahead of print on 8 June 2011 J. Clin. Microbiol. doi:10.1128/jcm.02087-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationDistribution of TEM, SHV and CTX-M Genes among ESBL-producing Enterobacteriaceae isolates in Iran
African Journal of Microbiology Research Vol. 6(26), pp. 5433-5439, 12 July, 2012 Available online at http://www.academicjournals.org/ajmr DOI: 10.5897/AJMR11.017 ISSN 1996-0808 2012 Academic Journals
More informationORIGINAL ARTICLE. Julie Creighton and Clare Tibbs. Canterbury Health Laboratories, Christchurch
ORIGINAL ARTICLE Evaluation of the MAST indirect carbapenemase test and comparison with a modified carbapenem inactivation method for the detection of carbapenemase enzymes in Gram-negative bacteria Julie
More informationAntimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin
Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin Matthew E. Falagas, Sofia Maraki, Drosos E. Karageorgopoulos, Antonia
More informationGlobal Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE)
Global Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE) Mitchell J. Schwaber, MD MSc Director, National Center for Infection Control Ministry of Health State of Israel November 27, 2012 1
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationTranslocation Studies Mid-Term Review (MTR) Meeting Marseille, France
Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding
More information(Plasmid mediated) Carbapenemases. Timothy R. Walsh, Cardiff University, Wales
(Plasmid mediated) Carbapenemases Timothy R. Walsh, Cardiff University, Wales What is a carbapenemase? How much carbapenem do they need to breakdown before they are called a carbapenemase? ESBL-enzymes
More informationORIGINAL ARTICLE SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN
SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN Anoop Sinha 1, Benny P V 2 HOW TO CITE THIS ARTICLE: Anoop Sinha, Benny PV. Susceptibility
More informationUTI can affect lower and sometimes both lower and upper urinary tracts. The term cystitis has been used to define the lower UTI infection and is
1. INTRODUCTION Infectious disease is a clinically evident condition that results from a pathogenic agent which includes bacteria, fungi, virus, protozoa, multi-cellular parasites and aberrant proteins
More informationInfection Control Strategies to Avoid Carbapenam Resistance in Hospitals. Victor Lim International Medical University Malaysia
Infection Control Strategies to Avoid Carbapenam Resistance in Hospitals Victor Lim International Medical University Malaysia Outline of Lecture 1. Carbapenam resistance 2. Epidemiology of carbapenam resistance
More informationCAT Critically Appraised Topic
CAT Critically Appraised Topic Part I: Evaluation of Three Different Agar Media for Rapid Detection of Extended- Spectrum β-lactamase Producing Enterobacteriaceae from Clinical Screening Samples. Part
More informationbla TEM bla CTX-M محمد مرتضي اردوني Extended-spectrum beta-lactamases ESBL Avian pathogenic Escherichia coli ESBLs (ESBLs)
bla bla -M 2 محمد مرتضي اردوني () -M ESBL bla bla -M -M bla bla -M Extended-spectrum beta-lactamases ESBL bla bla -M Avian pathogenic AEC Escherichia coli پست الکترونيک نويسندهي مسؤول: mjahantig@yahoo.com
More informationCephalosporin, Against Cephalosporin-Resistant Bacteria, and
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1979, P. 59-553 Vol. 16, No. 5 66-/79/11-59/$2./ Antibacterial Activity of Ceftizoxime (FK 79), a New Cephalosporin, Against Cephalosporin-Resistant Bacteria,
More informationCTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia
braz j infect dis. 2012;16(5):420 425 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original article CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from
More informationAgainst Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationTreatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae medicine.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producingescherichia-coli-klebsiella-pneumoniae/
More informationDetection of the KPC-2 Carbapenem-Hydrolyzing Enzyme in Clinical Isolates of ACCEPTED
JCM Accepts, published online ahead of print on April 00 J. Clin. Microbiol. doi:./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationORIGINAL INVESTIGATION. Rapid Spread of Carbapenem-Resistant Klebsiella pneumoniae in New York City
ORIGINAL INVESTIGATION Rapid Spread of Carbapenem-Resistant Klebsiella pneumoniae in New York City A New Threat to Our Antibiotic Armamentarium Simona Bratu, MD; David Landman, MD; Robin Haag, RN; Rose
More informationRecommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals
Recommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals Minnesota Department of Health 11/2011 Infectious Disease Epidemiology,
More informationRate of Transmission of Extended-Spectrum
MAJOR ARTICLE Rate of Transmission of Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae Without Contact Isolation Sarah Tschudin-Sutter, 1 Reno Frei, 2 Marc Dangel, 1 Anne Stranden, 1 and Andreas
More informationOther antimicrobials of interest in the era of extended-spectrum b-lactamases: fosfomycin, nitrofurantoin and tigecycline
REVIEW Other antimicrobials of interest in the era of extended-spectrum b-lactamases: fosfomycin, nitrofurantoin and tigecycline J. Garau Department of Medicine, Hospital Mutua de Terrassa, University
More informationNature and Science 2017;15(10)
Evaluation of Substrate Profile Test for Detection of Metallobetalactamses among Imipenem Resistant Clinical Isolates of Gram Negative Bacteria Tarek El-said El-Banna, Fatma Ibrahim Sonboland Eslam Shaaban
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More information